Proteome Sciences PLC (PRM) - Total Assets
Based on the latest financial reports, Proteome Sciences PLC (PRM) holds total assets worth GBX8.26 Million GBX (≈ $1.00K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Proteome Sciences PLC reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Proteome Sciences PLC - Total Assets Trend (1994–2025)
This chart illustrates how Proteome Sciences PLC's total assets have evolved over time, based on quarterly financial data. Check how high is Proteome Sciences PLC's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Proteome Sciences PLC - Asset Composition Analysis
Current Asset Composition (December 2025)
Proteome Sciences PLC's total assets of GBX8.26 Million consist of 25.1% current assets and 74.9% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 9.5% |
| Accounts Receivable | GBX754.00K | 9.1% |
| Inventory | GBX537.00K | 6.5% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX0.00 | 0.0% |
| Goodwill | GBX4.22 Million | 51.1% |
Asset Composition Trend (1994–2025)
This chart illustrates how Proteome Sciences PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PRM market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Proteome Sciences PLC's current assets represent 25.1% of total assets in 2025, a decrease from 87.6% in 1994.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2025, down from 84.5% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is goodwill at 51.1% of total assets.
Proteome Sciences PLC Competitors by Total Assets
Key competitors of Proteome Sciences PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.74 Billion |
|
Spectral Med Inc
TO:EDT
|
Canada | CA$8.12 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €13.12 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Proteome Sciences PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.13 | 0.18 | 0.37 |
| Quick Ratio | 0.09 | 0.13 | 0.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-14.50 Million | GBX-11.42 Million | GBX-7.27 Million |
Proteome Sciences PLC - Advanced Valuation Insights
This section examines the relationship between Proteome Sciences PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 974.68 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | GBX8.26 Million |
| Market Capitalization | $68.28K USD |
Valuation Analysis
Below Book Valuation: The market values Proteome Sciences PLC's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Proteome Sciences PLC's assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Proteome Sciences PLC (1994–2025)
The table below shows the annual total assets of Proteome Sciences PLC from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX8.26 Million ≈ $1.00K |
-10.34% |
| 2024-12-31 | GBX9.21 Million ≈ $1.12K |
-19.65% |
| 2023-12-31 | GBX11.46 Million ≈ $1.39K |
-100.00% |
| 2022-12-31 | GBX1.51 Trillion ≈ $184.17 Million |
+9.35% |
| 2021-12-31 | GBX1.38 Trillion ≈ $168.43 Million |
+2.58% |
| 2020-12-31 | GBX1.35 Trillion ≈ $164.20 Million |
+18.35% |
| 2019-12-31 | GBX1.14 Trillion ≈ $138.73 Million |
+0.61% |
| 2018-12-31 | GBX1.13 Trillion ≈ $137.89 Million |
+0.00% |
| 2017-12-31 | GBX1.13 Trillion ≈ $137.88 Million |
-6.58% |
| 2016-12-31 | GBX1.21 Trillion ≈ $147.60 Million |
+8.31% |
| 2015-12-31 | GBX1.12 Trillion ≈ $136.27 Million |
-17.52% |
| 2014-12-31 | GBX1.36 Trillion ≈ $165.22 Million |
+1.06% |
| 2013-12-31 | GBX1.34 Trillion ≈ $163.48 Million |
+19332952.37% |
| 2012-12-31 | GBX6.95 Million ≈ $845.60 |
-36.29% |
| 2011-12-31 | GBX10.91 Million ≈ $1.33K |
-30.06% |
| 2010-12-31 | GBX15.60 Million ≈ $1.90K |
+151.56% |
| 2009-12-31 | GBX6.20 Million ≈ $754.36 |
-3.76% |
| 2008-12-31 | GBX6.44 Million ≈ $783.81 |
-2.88% |
| 2007-12-31 | GBX6.63 Million ≈ $807.04 |
+3.71% |
| 2006-12-31 | GBX6.40 Million ≈ $778.21 |
-33.20% |
| 2005-12-31 | GBX9.57 Million ≈ $1.17K |
-7.42% |
| 2004-12-31 | GBX10.34 Million ≈ $1.26K |
-28.31% |
| 2003-12-31 | GBX14.43 Million ≈ $1.76K |
+4.35% |
| 2002-12-31 | GBX13.83 Million ≈ $1.68K |
+268.96% |
| 2001-12-31 | GBX3.75 Million ≈ $455.90 |
-11.10% |
| 2000-12-31 | GBX4.21 Million ≈ $512.84 |
+425.56% |
| 1999-12-31 | GBX802.00K ≈ $97.58 |
-57.63% |
| 1998-12-31 | GBX1.89 Million ≈ $230.32 |
-44.63% |
| 1997-12-31 | GBX3.42 Million ≈ $415.99 |
+464.19% |
| 1996-12-31 | GBX606.00K ≈ $73.73 |
-66.90% |
| 1995-12-31 | GBX1.83 Million ≈ $222.78 |
+338.04% |
| 1994-12-31 | GBX418.00K ≈ $50.86 |
0.00% |
| 1994-10-31 | GBX418.00K ≈ $50.86 |
-- |
About Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more